Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
作者信息
Russell Nigel, Burnett Alan, Hills Robert, Betteridge Sophie, Dennis Mike, Jovanovic Jelena, Dillon Richard, Grimwade David
机构信息
Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom.
出版信息
Blood. 2018 Sep 27;132(13):1452-1454. doi: 10.1182/blood-2018-05-851824. Epub 2018 Aug 10.
Abstract
摘要
相似文献
1
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.亚砷酸联合全反式维甲酸治疗初诊及复发急性早幼粒细胞白血病：AML17试验的长期随访
Blood. 2018 Sep 27;132(13):1452-1454. doi: 10.1182/blood-2018-05-851824. Epub 2018 Aug 10.
2
The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.中国三氧化二砷治疗初发急性早幼粒细胞白血病的经济学研究。
Cancer. 2020 Jan 15;126(2):311-321. doi: 10.1002/cncr.32519. Epub 2019 Nov 12.
3
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.诱导治疗结束时 PML-RARA 转录本水平与一线用全反式维甲酸加砷治疗的非高危急性早幼粒细胞白血病的预后相关：单中心队列研究的长期随访。
Br J Haematol. 2021 Dec;195(5):722-730. doi: 10.1111/bjh.17752. Epub 2021 Aug 17.
4
ATRA plus arsenic gets another "A" in APL.ATRA 联合砷剂在 APL 中获得又一个“成功”。
Blood. 2012 Aug 23;120(8):1535-6. doi: 10.1182/blood-2012-07-439547.
5
[Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].[急性早幼粒细胞白血病：全反式维甲酸和三氧化二砷的新治疗策略——AML-BFM推荐意见]
Klin Padiatr. 2018 Oct;230(6):299-304. doi: 10.1055/a-0750-5963. Epub 2018 Nov 6.
6
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.全反式维甲酸、三氧化二砷和吉妥单抗奥唑米星治疗急性早幼粒细胞白血病的2期研究长期随访
Cancer. 2025 Jan 1;131(1):e35662. doi: 10.1002/cncr.35662. Epub 2024 Nov 25.
7
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.口服砷剂联合维甲酸与静脉用砷剂联合维甲酸治疗非高危急性早幼粒细胞白血病的非劣效性、随机、3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5.
8
Long-term survey of outcome in acute promyelocytic leukemia.急性早幼粒细胞白血病的长期预后调查
Chin Med J (Engl). 2000 Feb;113(2):107-10. doi: 10.3901/jme.2000.08.107.
9
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.静脉注射三氧化二砷和全反式维甲酸作为低危急性早幼粒细胞白血病的一线治疗。
Expert Rev Hematol. 2019 Feb;12(2):81-87. doi: 10.1080/17474086.2019.1562332. Epub 2019 Jan 7.
10
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
引用本文的文献
1
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.可测量残留病（MRD）作为急性髓系白血病（AML）临床药物批准的替代终点：AML临床治疗联盟MRD合作与联盟的观点
Cancer. 2025 Jul 1;131(13):e35960. doi: 10.1002/cncr.35960.
2
Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the CONS.高危急性早幼粒细胞白血病患者需要进行为期1年的维持治疗——CONS研究。
Haematologica. 2025 Jul 1;110(7):1459-1465. doi: 10.3324/haematol.2025.287418. Epub 2025 Apr 3.
3
Acute myeloid leukemia management and research in 2025.2025年急性髓系白血病的管理与研究
CA Cancer J Clin. 2025 Jan-Feb;75(1):46-67. doi: 10.3322/caac.21873. Epub 2024 Dec 10.
4
A Patient with Acute Promyelocytic Leukemia Treated with Isotretinoin: A Case Report.一例接受异维A酸治疗的急性早幼粒细胞白血病患者：病例报告
Case Rep Oncol. 2024 Oct 1;17(1):1103-1108. doi: 10.1159/000541328. eCollection 2024 Jan-Dec.
5
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.复发急性早幼粒细胞白血病患者的缓解率及移植影响
Cancers (Basel). 2024 Sep 21;16(18):3214. doi: 10.3390/cancers16183214.
6
Current status and research directions in acute myeloid leukemia.急性髓细胞白血病的现状与研究方向。
Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2.
7
Therapy-related myeloid neoplasms following curative treatment of acute promyelocytic leukemia: incidence, correlation with therapeutic regimen, and future directions.急性早幼粒细胞白血病根治性治疗后与治疗相关的髓系肿瘤：发病率、与治疗方案的相关性及未来方向
J Hematop. 2024 Dec;17(4):201-208. doi: 10.1007/s12308-024-00606-6. Epub 2024 Sep 10.
8
Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy.急性早幼粒细胞白血病的诊断与管理：2024年巴西血液学、血液治疗与细胞治疗协会巴西共识指南
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):553-569. doi: 10.1016/j.htct.2024.05.002. Epub 2024 May 18.
9
Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.蒽环类药物-free 治疗在标准风险急性早幼粒细胞白血病中的优势：系统评价和比较流行病学分析。
Cancer Rep (Hoboken). 2024 Mar;7(3):e2035. doi: 10.1002/cnr2.2035.
10
CPX-351 and allogeneic stem cell transplant for a therapy-related acute myeloid leukemia that developed after treatment of acute promyelocytic leukemia: a case report and review of the literature.CPX-351与异基因干细胞移植治疗急性早幼粒细胞白血病治疗后发生的治疗相关急性髓系白血病：1例病例报告及文献复习
Front Oncol. 2024 Jan 25;13:1291457. doi: 10.3389/fonc.2023.1291457. eCollection 2023.
本文引用的文献
1
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.全反式维甲酸、三氧化二砷和吉妥单抗治疗急性早幼粒细胞白血病的长期疗效
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
2
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.维甲酸和三氧化二砷与维甲酸和化疗治疗非高危急性早幼粒细胞白血病的疗效比较：意大利-德国 APL0406 随机试验的最终结果。
J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.
3
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
4
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.全反式维甲酸和三氧化二砷联合治疗急性早幼粒细胞白血病。
N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.
5
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.在急性早幼粒细胞白血病的治疗中加入化疗（除蒽环类药物外）并不能改善预后：MRC AML15 试验的结果。
Leukemia. 2013 Apr;27(4):843-51. doi: 10.1038/leu.2012.360. Epub 2012 Dec 10.
6
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.急性早幼粒细胞白血病的管理：代表欧洲白血病网的专家小组建议
Blood. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Epub 2008 Sep 23.
7
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.急性髓系白血病（AML）患者中FLT3内部串联重复序列的存在为细胞遗传学风险分组及对首个化疗周期的反应增添了重要的预后信息：对来自英国医学研究委员会AML 10和12试验的854例患者的分析
Blood. 2001 Sep 15;98(6):1752-9. doi: 10.1182/blood.v98.6.1752.
Zotero 插件